Loading
An international consensus divided medulloblastoma into four molecular subgroups, WNT, SHH, group 3 and group 4, with different origins, genetics, ages and survival, a scheme now used in diagnosis and to design risk-adapted trials.
Consensus paper from medulloblastoma researchers reconciling several transcriptomic classifications into four subgroups (WNT, SHH, group 3, group 4), summarising their demographics, histology, genetics, clinical behaviour and outcomes, and proposing nomenclature for research and clinical use.
The medulloblastoma subtype pages on this site follow this scheme, which entered the WHO classification in 2016 and drives current de-escalation and intensification trials.
Shares WNT-activated medulloblastoma, Group 3 and group 4 medulloblastoma (non-WNT/non-SHH), SHH-activated medulloblastoma.
Shares WNT-activated medulloblastoma, Group 3 and group 4 medulloblastoma (non-WNT/non-SHH).
Shares WNT-activated medulloblastoma, Group 3 and group 4 medulloblastoma (non-WNT/non-SHH), SHH-activated medulloblastoma.
Shares WNT-activated medulloblastoma, Group 3 and group 4 medulloblastoma (non-WNT/non-SHH), SHH-activated medulloblastoma.
Shares WNT-activated medulloblastoma, Group 3 and group 4 medulloblastoma (non-WNT/non-SHH), SHH-activated medulloblastoma.
Shares WNT-activated medulloblastoma, Group 3 and group 4 medulloblastoma (non-WNT/non-SHH).
Shares WNT-activated medulloblastoma, Group 3 and group 4 medulloblastoma (non-WNT/non-SHH), SHH-activated medulloblastoma.
Shares WNT-activated medulloblastoma, Group 3 and group 4 medulloblastoma (non-WNT/non-SHH), SHH-activated medulloblastoma.